Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association最新文献

{"title":"Keluoxin inhibits the progression of Diabetic Kidney Disease via TNF-α/IKKβ/IκBα/NF-κB p65 signaling pathway.","authors":"Hanrong Zhang, Manlu Xiao, Wenjing Ye, Nan Xiao, Jiayi Luo, Yijie Jia, Qiaoqi Yang, Xiaoqin Ma, Zongji Zheng, Junyu Xue, Yaoming Xue","doi":"10.1055/a-2911-9625","DOIUrl":"10.1055/a-2911-9625","url":null,"abstract":"<p><strong>Abstract: </strong>BACKGROUND: Previous clinical studies have indicated that Keluoxin can be used for the treatment of diabetic kidney disease. However, the specific mechanisms involved and the primary effective components have not been fully explored.</p><p><strong>Abstract: </strong>PURPOSE: The purpose of this study was to investigate the protective mechanisms of Keluoxin and its main components against diabetic kidney disease.</p><p><strong>Abstract: </strong>METHODS: The animal models included db/db mice treated with Keluoxin or saline and db/m mice treated with saline. Astragaloside IV was used to treat human kidney-2 cells for in vitro experiments. To assess the effects of Keluoxin on diabetic kidney disease, serum biochemical parameters and tissue histopathological staining were examined. Western blotting and the quantitative real-time polymerase chain reaction were employed to detect the expression levels of fibrosis and inflammation markers. RNA sequencing was conducted on the samples, and downstream mechanisms were validated at the level of animal tissues and cells.</p><p><strong>Abstract: </strong>RESULTS: Keluoxin significantly reduced blood glucose and urinary microalbumin in db/db mice, alleviated renal tubular damage, inflammation and fibrosis in diabetic kidney disease mice, and did not cause any damage to liver function. Sequencing results indicated that Keluoxin modulated the tumor necrosis factor signaling pathway, nuclear factor kappa light chain enhancer of activated B cell signaling pathway and inflammatory responses. In vivo experiments showed that Keluoxin inhibits the tumor necrosis factor alpha/inhibitor of kappa B kinase beta/inhibitor of nuclear factor kappa B alpha/nuclear factor kappa light chain enhancer of activated B cell p65 pathway, thereby providing protection against diabetic kidney disease. Immunoinfiltration analysis indicated that Keluoxin reduced neutrophil infiltration in the renal cortex of diabetic kidney disease mice. Through pharmacological component analysis, we determined that astragaloside IV is the main component of Keluoxin. In vitro experiments showed that astragaloside IV also alleviated the inflammatory response and fibrosis, inhibiting the expression of the tumor necrosis factor alpha/inhibitor of kappa B kinase beta/inhibitor of nuclear factor kappa B alpha/nuclear factor kappa light chain enhancer of activated B cell p65 signaling pathway.</p><p><strong>Abstract: </strong>CONCLUSIONS: Keluoxin exerts renal protective effects by inhibiting the tumor necrosis factor alpha/inhibitor of kappa B kinase beta/inhibitor of nuclear factor kappa B alpha/nuclear factor kappa light chain enhancer of activated B cell p65 signaling pathway with astragaloside IV being the primary active component.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Oral Antidiabetic Drugs on Metabolic Dysfunction-associated Steatotic Liver Disease Progression in Patients with Type 2 Diabetes: A Retrospective Cohort Study.","authors":"Vasileios Petrakis, Petros Rafailidis, Anastasia Grapsa, Anastasia Sousanidou, Touba Bougiouklou, Nikoleta Babaka, Periklis Panagopoulos, Dimitrios Papazoglou","doi":"10.1055/a-2897-4761","DOIUrl":"10.1055/a-2897-4761","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease is highly prevalent among patients with type 2 diabetes mellitus, exacerbating the risk of severe hepatic and cardiovascular complications. While metformin remains the first-line therapy, the optimal second-line oral antidiabetic drug for mitigating liver disease progression remains unclear.</p><p><strong>Patients and methods: </strong>This retrospective observational study (2019-2023) evaluated 250 patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (defined by a fatty liver index score of>60) treated at the Outpatient Clinics of the 2^nd University Department of Internal Medicine of University General Hospital of Alexandroupolis (Greece). Patients were on baseline metformin and initiated one of four oral antidiabetic drug classes: sodium-glucose cotransporter-2 inhibitors (<i>n </i>= 72), thiazolidinediones (<i>n</i>=36), dipeptidyl peptidase-4 inhibitors (<i>n</i>=77), and sulfonylureas (<i>n</i>=65). The primary end point was metabolic dysfunction-associated steatotic liver disease regression (a fatty liver index score of<30). The secondary end point encompassed severe liver-related outcomes and mortality.</p><p><strong>Results: </strong>Sodium-glucose cotransporter-2 inhibitors demonstrated the highest probability of metabolic dysfunction-associated steatotic liver disease regression compared to sulfonylureas (adjusted sub-distribution hazard ratio: 1.99 and 95% confidence interval: 1.75-2.27), dipeptidyl peptidase-4 inhibitors (adjusted sub-distribution hazard ratio: 1.45 and 95% confidence interval: 1.30-1.62), and thiazolidinediones (adjusted sub-distribution hazard ratio: 1.40 and 95% confidence interval: 1.12-1.75). Furthermore, sodium-glucose cotransporter-2 inhibitors significantly reduced the risk of severe liver-related outcomes compared to sulfonylureas (adjusted sub-distribution hazard ratio: 0.37 and 95% confidence interval: 0.17-0.82).</p><p><strong>Conclusions: </strong>In patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease, the addition of sodium-glucose cotransporter-2 inhibitors to metformin significantly promotes fatty liver regression and protects against severe liver-related outcomes compared to other standard oral antidiabetic drug classes.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge of Cardiovascular Disease Risk and Lifestyle Behaviors among Adults with Metabolic Syndrome: A Cross-Sectional Study.","authors":"Aylia M Yesilova, Münevver G Avşar, Sedat Özdemir, Arzu Erkoç, Sezin Dogan Cakir, Orkide Kutlu, Mine Adaş","doi":"10.1055/a-2899-6146","DOIUrl":"10.1055/a-2899-6146","url":null,"abstract":"<p><strong>Abstract: </strong>BACKGROUND: Cardiovascular disease remains the leading cause of mortality worldwide, largely driven by modifiable cardiometabolic risk factors. Adults with metabolic syndrome represent a particularly high cardiometabolic risk group in whom preventive strategies are crucial; however, their level of knowledge regarding cardiovascular disease, its risk factors, and related lifestyle behaviours remains insufficiently characterized. This study aimed to assess the knowledge of cardiovascular disease and its risk factors among adults with metabolic syndrome and examine their associations with lifestyle behaviors and metabolic control.</p><p><strong>Abstract: </strong>METHODS: In this single-center cross-sectional study, 350 adults with metabolic syndrome diagnosed according to Adult Treatment Panel III criteria were evaluated. Cardiovascular knowledge was assessed using the validated Cardiovascular Disease Risk Factor Knowledge Level scale. Lifestyle behaviors, anthropometric measurements, laboratory parameters, and medication use were recorded. Associations between Cardiovascular Disease Risk Factor Knowledge Level scores and patient characteristics, lifestyle behaviours, and metabolic control were examined.</p><p><strong>Abstract: </strong>RESULTS: The mean age of the study population was 45.7±11.5 years, and 72% were women. The mean total Cardiovascular Disease Risk Factors Knowledge Level score was 21±3, with 42% of participants demonstrating high knowledge levels (≥80% correct responses). Despite this, adherence to lifestyle recommendations was suboptimal, with only 6% reporting regular physical activity and 26% adhering to dietary recommendations. Notably, only 9% of participants were aware of their metabolic syndrome diagnosis. Higher knowledge scores were associated with higher educational level, better dietary adherence, and lipid-lowering therapy use (<i>p</i><0.05), as well as lower rates of smoking and alcohol consumption. However, no significant associations were observed with physical activity or weight-related measures.</p><p><strong>Abstract: </strong>CONCLUSIONS: Although adults with metabolic syndrome demonstrated the moderate to high awareness of cardiovascular disease and its risk factors, this knowledge did not consistently translate into healthier lifestyle behaviors. Prevention strategies targeting high cardiometabolic-risk populations should extend beyond information dissemination and incorporate behavioral and motivational components to improve cardiovascular outcomes.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148304169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Fibroblast Growth Factor 21 with Excessive Intrapancreatic Fat Deposition in Type 2 Diabetes Mellitus.","authors":"Beste Ozturk, Mustafa Comoglu, Oguzhan Zengin, Esma Andac Uzdogan, Emre Buyukkaplan, Emra A Kalkan, Ihsan Ates","doi":"10.1055/a-2899-6872","DOIUrl":"https://doi.org/10.1055/a-2899-6872","url":null,"abstract":"<p><strong>Abstract: </strong>OBJECTIVES: Fibroblast growth factor 21 is a metabolic regulator involved in glucose and lipid homeostasis. However, its relationship with excessive intrapancreatic fat deposition in type 2 diabetes mellitus remains unclear. We aimed to evaluate the association between serum fibroblast growth factor 21 levels and excessive intrapancreatic fat deposition in patients with type 2 diabetes mellitus.</p><p><strong>Abstract: </strong>METHODS: This prospective cross-sectional study included 101 participants who had previously undergone abdominal computed tomography. Group 1 consisted of patients with type 2 diabetes mellitus and excessive intrapancreatic fat deposition (<i>n</i>=31), Group 2 consisted of patients with type 2 diabetes mellitus without excessive intrapancreatic fat deposition (<i>n</i>=40), and Group 3 consisted of individuals without type 2 diabetes mellitus or excessive intrapancreatic fat deposition (<i>n</i>=30). Excessive intrapancreatic fat deposition was assessed on computed tomography by a blinded radiologist. Correlation, multivariable logistic regression, and receiver operating characteristic analyses were performed.</p><p><strong>Abstract: </strong>RESULTS: Fibroblast growth factor 21 levels were higher in Group 1 than in Groups 2 and 3 (82.32 pg/mL vs. 48.36 pg/mL vs 48.36 pg/mL, respectively; <i>p</i><0.001). Serum fibroblast growth factor 21 levels were inversely correlated with the pancreas-to-spleen ratio in the overall cohort (<i>ρ</i>=- 0.527, <i>p</i><0.001) and in the type 2 diabetes mellitus subgroup (<i>ρ</i>=- 0.510, <i>p</i><0.001). In multivariate analysis, higher serum fibroblast growth factor 21 levels were independently associated with excessive intrapancreatic fat deposition both in the subgroup with diabetes (odds ratio: 1.03, 95% confidence interval: 1.01-1.05; <i>p</i>=0.004) and in the overall study population (odds ratio: 1.03, 95% confidence interval: 1.01-1.05; <i>p</i>=0.003). Receiver operating characteristic analysis showed an area under the curve (AUC) of 0.796 for fibroblast growth factor 21 in predicting excessive intrapancreatic fat deposition. A fibroblast growth factor 21 cutoff value of>62.15 pg/mL yielded a sensitivity of 83.87% and a specificity of 67.14%.</p><p><strong>Abstract: </strong>CONCLUSIONS: Serum fibroblast growth factor 21 levels were increased in patients with type 2 diabetes mellitus and excessive intrapancreatic fat deposition and were independently associated with excessive intrapancreatic fat deposition. Circulating fibroblast growth factor 21 may reflect pancreatic fat accumulation in the setting of metabolic dysfunction.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148383383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Carcinoembryonic Antigen, Carbohydrate Antigen, Neuron-specific Enolase and Lipid Profile to Predict the Occurrence, Pathological Grading and Metastasis of Pancreatic Neuroendocrine Tumors.","authors":"Jingjing Zhang, Xiaofeng Jia, Yanling Xu, Feiyu Lu, Jinxing Bao, Mujie Ye","doi":"10.1055/a-2866-8701","DOIUrl":"10.1055/a-2866-8701","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the diagnostic value of serum carcinoembryonic antigen, carbohydrate antigen, neuron-specific enolase, and lipid metabolism markers (total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) in pancreatic neuroendocrine tumors.</p><p><strong>Methods: </strong>A total of 175 pancreatic neuroendocrine tumor patients (experimental group) and 88 healthy individuals (control group) were enrolled. Serum levels of carcinoembryonic antigen, carbohydrate antigen, neuron-specific enolase, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and body mass index were analyzed. A logistic regression analysis model was constructed, and the receiver operating characteristic curve was utilized to evaluate the efficacy of individual indicators with statistically significant differences, as well as the combined detection model, in predicting the occurrence, pathological grading, and metastasis of pancreatic neuroendocrine tumors.</p><p><strong>Results: </strong>Pancreatic neuroendocrine tumor patients showed higher levels of carcinoembryonic antigen, neuron-specific enolase, low-density lipoprotein cholesterol and lower levels of high-density lipoprotein cholesterol than the control group. High-grade pancreatic neuroendocrine tumor patients showed higher carcinoembryonic antigen, carbohydrate antigen, neuron-specific enolase, total cholesterol, and low-density lipoprotein cholesterol levels than low-grade cases, with increased metastasis risk. Elevated carcinoembryonic antigen, carbohydrate antigen, and neuron-specific enolase levels were linked to metastasis. The results are statistically significant. High neuron-specific enolase and low high-density lipoprotein cholesterol were pancreatic neuroendocrine tumor risk factors, with area under the curves of 0.899 and 0.666, respectively, improving to 0.911 when combined. Elevated carbohydrate antigen and neuron-specific enolase levels predicted high-grade (area under the curves: 0.728, 0.645; combined area under the curve: 0.765) and metastatic pancreatic neuroendocrine tumors (area under the curves: 0.693, 0.651; combined area under the curves: 0.689).</p><p><strong>Conclusions: </strong>Increased neuron-specific enolase is a strong predictor of pancreatic neuroendocrine tumor occurrence, grading, and metastasis. Lower high-density lipoprotein cholesterol predicts pancreatic neuroendocrine tumor occurrence but not grading or metastasis. Combined markers enhance diagnostic accuracy for pancreatic neuroendocrine tumor detection and grading.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"227-233"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose Monitoring and Control Testing in Patients with Type 1 or Type 2 diabetes.","authors":"Sandra Schlüter, Dorothee Deiss, Bernhard Gehr, Karin Lange, Simone von Sengbusch, Andreas Thomas, Ralph Ziegler, Tobias Wiesner, Guido Freckmann","doi":"10.1055/a-2766-3426","DOIUrl":"10.1055/a-2766-3426","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"206-221"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes Mellitus and the Heart.","authors":"Katharina Marx-Schütt, Thomas Forst, Andreas L Birkenfeld, Andreas Zirlik, Dirk Müller-Wieland, Nikolaus Marx","doi":"10.1055/a-2766-3079","DOIUrl":"10.1055/a-2766-3079","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"222-226"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148058961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Definition, Classification, Diagnostics and Differential Diagnostics of Diabetes Mellitus: Update 2025.","authors":"Rüdiger Landgraf, Lutz Heinemann, Toralf Schwarz, Christoph Niederau, Stefan Pleus, Andrea Tytko, Christoph Werner, Dirk Müller-Wieland, Ulrich A Müller, Guido Freckmann, Erwin Schleicher, Anette-Gabriele Ziegler, Matthias Nauck, Astrid Petersmann","doi":"10.1055/a-2766-3155","DOIUrl":"10.1055/a-2766-3155","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"182-195"},"PeriodicalIF":1.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Diabetes Stigma in German People With Diabetes: Psychometric Validation of the German Versions of the Diabetes Stigma Assessment Scales (DSAS-1 and DSAS-2).","authors":"Laura Yvonne Klinker, Andreas Schmitt, Dominic Ehrmann, Lilli-Sophie Priesterroth, Timm Roos, Jane Speight, Elizabeth Holmes-Truscott, Bernhard Kulzer, Norbert Hermanns","doi":"10.1055/a-2835-0606","DOIUrl":"10.1055/a-2835-0606","url":null,"abstract":"<p><strong>Aims: </strong>To develop and evaluate the German versions of the Diabetes Stigma Assessment Scales for type 1 (DSAS-1) and type 2 diabetes (DSAS-2).</p><p><strong>Methods: </strong>The questionnaires were translated using a standardized translation and back-translation procedure. Adults with type 1 (<i>N</i>=636) and type 2 diabetes (<i>N</i>=177) completed the DSAS-1 and DSAS-2 via an online panel. Factor analyses, internal consistency (Cronbach's <i>α</i>), and correlations with convergent measures and discriminant constructs were conducted to assess reliability and validity.</p><p><strong>Results: </strong>For the DSAS-1, the expected three-factor structure was confirmed; for the DSAS-2, a two-factor solution emerged, although a forced three-factor analysis supported the original structure with minor cross-loadings. Scale consistencies were excellent (DSAS-1: 0.94, DSAS-2: 0.95, and subscales: 0.86-0.93). Both scales showed good concurrent, convergent and discriminant validity. The DSAS-2 showed stronger associations with weight self-stigma and self-esteem than the DSAS-1, consistent with its focus on internalized stigma. Three in four persons (type 1 diabetes: 74% and type 2 diabetes: 72%) endorsed at least one stigma item, mostly related to \"blame and judgement.\"</p><p><strong>Conclusions: </strong>Diabetes stigma constitutes an important psychosocial problem. The German DSAS-1and DSAS-2 are reliable, valid instruments for assessing diabetes stigma. Blame and judgement appeared as the most common form of stigma experienced in this sample.</p>","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"196-201"},"PeriodicalIF":1.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid Therapy in Patients with Diabetes Mellitus.","authors":"Klaus G Parhofer, Andreas L Birkenfeld, Wilhelm Krone, Michael Lehrke, Nikolaus Marx, Martin Merkel, Katharina Marx-Schütt, Andreas Zirlik, Dirk Müller-Wieland","doi":"10.1055/a-2766-1520","DOIUrl":"10.1055/a-2766-1520","url":null,"abstract":"","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"175-180"},"PeriodicalIF":1.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147701284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}